Drug Discovery
ByDrugmakers Use AI to Speed Trials and Regulatory Filings
Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines PepGen’s experimental Duchenne…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
